Rob Cannings has joined Exosect as director of business development.
Following Exosect’s recent announcement of its move to a licensing business model, Cannings will lead the business development team and be responsible for out-licensing Exosect’s proprietary formulation delivery platforms, Entostat and Entomag.
He brings with him over 25 years of global biological and agrochemical experience across a wide range of markets, most recently the marketing of biopesticides within Bayer.
Canning's previous roles have included product, portfolio and technology management roles in Agraquest, Chemtura, Scotts, Zeneca and ICI.
Exosect’s CEO, Martin Brown, said: “Rob has a great deal of experience in both the synthetic and biological pesticide markets. He is therefore very well placed to drive out-licensing projects on our technology platforms. We are very pleased to welcome him to the team.'
Exosect is a venture capital funded technology company.
It was launched in 2001 to develop proprietary platform technologies, initially for agriculture.
No comments yet